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Abstract
A need still exists to determine the clinical and neurophysiological characteristics
of leprosy neuropathy at distinct times of the disease by different methods that
measure the various nerve ﬁber functions. A prospective clinical study was per-
formed with 10 paucibacillary (PB) and 12 multibacillary (MB) patients evaluated
at diagnosis and one year after cessation of multidrug therapy (MDT). Peripheral
nerve function was assessed clinically and by means of the sympathetic skin re-
sponse, skin vasomotor reﬂex, and nerve conduction study (NCS). At diagnosis,
73% of the total 22 patients had nerve function impairment (NFI). Autonomic
function (χ2 = 5.5, P = 0.019) and NCS (χ2 = 7.765, P = 0.01) were signiﬁcantly
more altered in MB than PB patients. At ﬁnal evaluation, NFI of the MB patients
had worsened, especially among the six who had leprosy reaction. As the NFI of
PB patients showed improvement, a signiﬁcant difference between the two groups
(χ2 = 12.320, P = 0.001) was observed. A high prevalence of neuropathy was
observed in newly diagnosed patients. Associating different tests with a thorough
clinical neurological evaluation increases detection rates.
Introduction
Leprosy,adiseaseknownforitscharacteristicinsensitiveskin
patches, is the main cause of peripheral neuropathy in en-
demic countries. Neuropathy is often clinically silent in its
evolution making early diagnosis exceptionally challenging
so that even highly skilled clinical management may not be
able to prevent permanent nerve damage (Job 1989).
The Enhanced Global Strategy for 2011–2015 emphasizes
the goal of reducing the number of patients with permanent
disabilities,whichin2009totaled14,320newpatients(WHO
2010).Fortunately,crucialinformationconcerningtheetiol-
ogy, incidence, risk factors, and treatment of peripheral neu-
ropathy is becoming more and more readily available despite
the fact that many key questions regarding early diagnosis
and prevention strategies continue unanswered.
Clinical neurological examination, especially of sensory
function, is essentially subjective in that it is based on a cer-
tain level of patient awareness. Accordingly, distinct tech-
niques aiming toward a more objective detection of early
nerve function impairment (NFI), imperative for successful
therapeutic interventions, have been developed and tested
(Van Brakel et al. 2007).
Nerve conduction study (NCS) provides reliable informa-
tion regarding large myelinated nerve ﬁber (LNF) impair-
ment, often a late event in leprosy (Anthia et al. 1975). How-
ever, a special approach is required to detect impairment
of the small, nonmyelinated and poorly myelinated ﬁbers
that are so, particularly vulnerable to early damage from the
Mycobacterium leprae (M. leprae)-induced inﬂammatory in-
ﬁltrate (Rambukkana 2000). Speciﬁcally, autonomic abnor-
malitiescanbeeffectivelystudiedbymeasuringtheskinvaso-
motor reﬂex (SVMR) (Low et al. 1983) and the sympathetic
skin response (SSR) (Shahani et al. 1984).
Leprosy neuropathy is complex, with the superposition
of acute and chronic sensory, motor and/or autonomic
events (Charosky and Cardama 1983). A prospective clinical
study was performed in newly diagnosed leprosy patients
to evaluate the small and large myelinated ﬁbers by means
of clinical neurological examination and neurophysiological
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studies. The different methods were applied to determine
the frequency of neuropathy at diagnosis and one year after
cessation of multidrug therapy (MDT) in paucibacillary
(PB) and multibacillary (MB) leprosy patients.
Patients and Methods
Twenty-two leprosy patients (16 men and six women, aged
19–60) diagnosed at the Leprosy Outpatient Clinic, Oswaldo
Cruz Foundation, Rio de Janeiro, RJ, Brazil, were evaluated
prior to and one year after cessation of MDT and consec-
utively selected regardless of their neurological condition.
Patients with associated diseases such as diabetes mellitus,
alcoholism, Human immunodeﬁciency virus or Human T-
linphotroﬁc virus-I infections, rheumatoid/rheumatic dis-
eases,orwithtoxic,drug-induced,orhereditaryneuropathies
were excluded. All patients received MDT: PB patients with
no observable bacilli in six slit-skin smears (baciloscopic in-
dex = 0) were treated for six months with one supervised
monthly dose of 600 mg rifampicin and 100 mg dapsone
in conjunction with 100 mg/day dapsone; MB patients with
positive slit-skin smears to M. leprae,r e c e i v e dam o n t h l ys u -
pervised dose of 600 mg rifampicin, 100 mg dapsone, and
300 mg clofazimine together with 100 mg/day dapsone and
50 mg/day clofazimine for 12 months. Upon completion of
MDT, the patients were directed to return in the case of the
development of new lesions, the worsening of old ones, or
t h ea p p e a r a n c eo fn e u r o l o g i c a ls y m p t o m s .
The research was carried out in compliance with the In-
ternational Norms on Ethics in Human Research, having
been previously approved by the Ethics Committee of the
Oswaldo Cruz Foundation. All patients voluntarily provided
their written, informed consent.
A clinical neurological evaluation of the peripheral nerves
of all patients was performed. LNF were complementarily
evaluated by means of NCS and autonomic function via
SVMR and SSR. The evaluations at diagnosis and one year
after cessation of MDT were performed by different neurol-
ogists.
A detailed neurologic examination was performed to
record the number and distribution of affected nerves. The
analyzed components of the neurologic examination were:
motor strength and tactile sensation for LNF evaluation,
thermal and pain sensation, presence of cyanosis on the
palms and/or soles, and paraesthesia for the small nerve
ﬁber (SNF) evaluation. Sensory impairment, motor deﬁcit,
and disability/deformity status were assessed using standard
methods.
In brief, tactile threshold was tested with Semmes-
Weinsteinmonoﬁlaments.Themonoﬁlamentsvaryinthick-
ness, with a different value in grams for each one (1 = 300 g,
2 = 4g ,3= 2g ,4= 0.2 g, and 5 = 0.05 g), and the inability
to perceive the touch of even one of them represents an ab-
sence of tactile sensitivity to that given pressure (Minist´ erio
da Sa´ ude 2001, 2002). Thermal sensation was determined by
theuseofcoldmetal(15◦Ccold)objects,andasafetypinwas
utilizedtoascertainpainperceptioninthemedian,ulnar,ra-
dial, sural, superﬁcial ﬁbular, and plantar bilaterally nerves.
Individual muscle strength of the upper and lower extrem-
ities was determined by voluntary muscle testing. Disability
was recorded in accordance with the standard World Health
Organizationgradingcriteria(WHO1988).NFIwasdeﬁned
as clinically detectable impairment of the motor, sensory,
and/or autonomic functions.
The following tests were used in the neurophysiological
studies for the SNF evaluation:
SVMR was tested by means of a Laser-Doppler ﬂuxome-
ter (Periﬂux 5000 system, PERIMEDTM, Stockholm, Swe-
den)accordingtoIllarramendietal.(2005).Inbrief,patients
were requested to refrain from eating, drinking any caffeine-
containing beverages, and smoking for 3 h prior to exami-
nation. All individuals were tested in the morning hours to
reduce the effect of the circadian variation in the peripheral
blood ﬂow. Blood perfusion was measured on the ﬁngertips
ofthesecondandﬁfthdigitsusingsmall,angledthermostatic
probesattachedbydouble-sidedadhesivestrips.Theinspira-
tory gasp—a sudden, deep, full inspiration without holding
thebreath—wasusedtostimulatetheSVMR.Baselineblood
perfusion was registered after the individuals were comfort-
ably seated with their arms on a table at heart level. The
onset of the stimulus was marked and the resultant variation
in skin blood perfusion was recorded. The procedure was
repeated at least three times and the two largest reductions
wereaveraged.Thereductioninperfusionwasexpressedasa
percentageofthebaselinebloodperfusion.AbnormalSVMR
wasdeﬁnedasthe95thpercentileofthevaluesobtainedfrom
an endemic control group (Illarramendi et al. 2005).
SSRwasrecordedbywayofaconventionalelectromyogra-
phyapparatus:theNeuropack2(Nihon-Koden)two-channel
system.Surfacediscelectrodeswereappliedtotheventraland
dorsalsurfacesofthehand.Recordingswereﬁlteredataband
p a s so f0 . 5 – 1K H zw i t ha na n a l y t i c a lt i m eo f5s e c .Aﬁ x e d
stimulus of 0.2 msec duration and 25 mA intensity was ap-
pliedtothemediannerveattheoppositewrist.Applicationof
random stimuli of sufﬁcient intensity was used to overcome
habituation. Only the absence of response was considered
abnormal.
LNFs were measured via NCS that was performed using
the same Nihon-Koden apparatus in accordance with stan-
dardprocedures(Delisaetal.1994).Amplitude,velocity,and
latencywererecordedforthemedian,radial,ulnar,andsural
sensorynervesinadditiontothemedian,ulnar,andperoneal
motor nerves (total of 14 nerves). Lower limits of normal
(cutoff) for sensory conduction velocity (m/sec) were: radial
(41), median (42), ulnar (43), sural (38); for sensory ampli-
tude (μV) were: radial (8), median (15), ulnar (8), sural (7).
Lower limits of normal (cutoff) for motor conduction veloc-
ity (MVC) (m/sec) were: median (52), Ulnar (55), Peroneal
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(42); for motor amplitude (mV) were: median (4), ulnar (4),
peroneal(2).Theupperlimitsofnormal(cutoff)forsensory
latency (milliseconds) were: radial (2.2), median (3.4), ulnar
(2.7), sural (3.6) and for motor latency were: median (3.8),
ulnar (3.3), peroneal (4.6).
The results of the conduction studies were used to deter-
mine LNF impairment and classiﬁed, as follows: (1) normal;
(2)axonallesion,deﬁnedbyareductionofCompoundMus-
cle Action Potentials (CMAP) and/or Sensory Nerve Action
Potentials (SNAP), the amplitude being less than 30% of
reference values and the sensory and/or MVC above 70%
of reference value; (3) demyelination lesion, deﬁned when
the CMAP and/or SNAP latency prolonged compared to the
reference value together with a reduction of sensory and/or
MCV below 85% of reference value; (4) mixed lesion, when-
ever there were both axonal and demyelinating lesions in the
same nerve; and (5) no conduction. Abnormal temporal dis-
persion was deﬁned as a proximal distal compound muscle
action potential duration increase of more than 30% (Olney
et al. 2003).
Data were analyzed via SPSSTM 11.5 for Windows. The
χ2, the Fisher’s exact, and the Mann–Whitney U tests were
utilized to compare PB and MB patient variables. The ﬁrst
and second exams were compared by the McNemar test; and
P values under 0.05 were considered signiﬁcant.
Results
Ten(45%)patientsreceivedthePBscheme(accordingtotype
ofleprosy:oneindeterminate,onetuberculoid,andeightbor-
derline tuberculoid); and 12 (55%) received the MB scheme
(fourborderlinelepromatousandeightlepromatous).Before
treatment, most of the MB patients (92%) had a high (≥3.0)
baciloscopic index. While 90% of all MB patients were male,
only 50% of PB patients were (P = 0.056).
A majority of the PB (90%) and MB (58%) patients had
no observable disability at diagnosis according to grade of
disability,but 73% of the 22 patients had NFI. All of the clin-
ical parameters showed a nonsigniﬁcant higher percentage
of alteration in MB as compared to PB patients (Table 1).
While eight (36%) of the 22 patients (ﬁve MB) had nerve
enlargement,nonecomplainedofnervetendernessandwere
thus not diagnosed with acute neuritis. All patients (n = 12)
who had at least one sensory nerve impairment had thermal
and/orpainimpairment,sixofwhomhadtactileimpairment
as well.
Eightpatients(36%)hadalteredSVMR,sevenontheulnar
topography (85% bilaterally), and ﬁve on the median topog-
raphy(40%bilaterally).SSRwasabsentineight(36%)ofthe
patients. MB patients evidenced more frequent impairments
onbothtests,butonlySVMR(T able2)wassigniﬁcantlymore
altered in MB than PB patients (χ2 = 5.5, P = 0.019). In-
terestingly, an association of the SVMR with the SNF clinical
examination was observed in this sample of patients. Of the
four patients with SNF clinical impairment, all had SVMR
dysfunction (χ2 = 8.556, P = 0.010).
Five (23%) patients (all PB) had a normal NCS. The NCS
result was signiﬁcantly more compromised in MB than PB
patients (χ2 = 7.765, P = 0.01) in both the motor (χ2 =
9.900, P = 0.003) and sensory nerves (χ2 = 6.712, P =
0.02) (Table 1). In addition, temporal dispersion was only
observed in three patients: two in the ulnar and one in the
median nerves.
Sensory and motor alteration was more evident in the
NCS than in the respective clinical parameters. For example,
althoughnotactilesensoryimpairmentoftheulnarnervewas
Table 1. Neuropathy evaluation in paucibacillary (PB) and multibacillary (MB) patients: comparison between PB (n = 10) and MB (n = 12) patients
(
∗P value of Fisher’s exact test), at diagnosis and follow-up (
∗∗P value of McNemar test).
SNFi LNFi NCS
Group T/P MFT VMT NFI Sensory Motor Total
At diagnosis
PB 40% 20% 0% 60% 40% 40% 50%
MB 67% 33% 17% 83% 92% 100% 100%
∗P 0.391 0.646 0.481 0.348 0.020 0.003 0.010
Follow-up
PB 20% 10% 0% 30% 60% 70% 70%
MB 83% 25% 25% 100% 92% 83% 92%
∗P 0.008 0.594 0.221 0.001 0.135 0.624 0.293
∗∗P (at diagnosis and follow-up)
PB 0.625 1.000 – 0.375 0.625 0.250 0.625
MB 0.500 1.000 1.000 0.479 1.000 0.500 1.000
SNFi, small nerve ﬁber impairment; LNFi, large nerve ﬁber impairment; NFI, nerve function impairment; NCS, nerve conduction study; T/P, thermal
and/or pain; MFT, monoﬁlament test; VMT, voluntary muscle test; –, not done due to 0 values.
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Table 2. Clinical and neurophysiological ﬁndings in ulnar and median nerves.
Clinical impairment NCS
Nerve Group Pc Sen T/P MFT VMT SVMR sNCS mNCS
At diagnosis
Ulnar PB 10% 10% 10% 0% 0% 20% 10% 30%
MB 67% 25% 25% 0% 0% 38% 67% 79%
∗P <0.001 0.259 0.259 – – 0.205 <0.001 0.003
Median PB 10% 0% 0% 0% 0% 0% 15% 10%
MB 67% 13% 13% 0% 0% 29% 50% 67%
∗P <0.001 0.239 0.239 – – 0.011 0.034 <0.001
Follow-up
Ulnar PB 5% 0% 0% 0% 0% 15% 40% 50%
MB 21% 17% 17% 4% 8% 13% 75% 42%
∗P 0.197 0.114 0.114 1.000 0.493 1.000 0.041 0.800
Median PB 5% 0% 0% 0% 0% 10% 15% 35%
MB 21% 17% 17% 0% 0% 13% 67% 54%
∗P 0.197 0.114 0.114 – – 1.000 <0.001 0.330
∗∗P (at diagnosis and follow-up)
Ulnar PB 1.000 – – – – 1.000 0.980 0.157
MB 0.003 0.500 0.500 – – 0.031 0.660 0.014
Median PB 1.000 – – – – – 1.000 0.025
MB 0.003 1.000 1.000 – – 0.344 0.194 0.317
Pc, palmar cyanosis; Sen, sensory impairment; PB, paucibacillary; MB, multibacillary; SVMR, skin vasomotor reﬂex; NCS, nerve conduction study; sNCS,
sensory nerve conduction study; mNCS, motor nerve conduction study; T/P, thermal and/or pain impairment; MFT, monoﬁlament test; VMT, voluntary
muscle test impairment; –, not done due to 0 values.
∗P value of Fisher’s exact test used to compare variables between PB and MB patients;
∗∗P value of McNemar test used to compare variables at diagnosis
and follow-up.
clinically observed, the NCS showed sensory dysfunction in
41%(18/44)ofallulnarnerves(Table2).Amongthesensory
nerves, the most commonly clinically affected were those of
thelowerextremities,namely,thecalcanealandplantar(19%
and 14%, respectively), followed by the sural and superﬁcial
peroneal (13% each), while the sural nerve was the most
impaired (43% with no conduction) in the NCS. Similarly,
even though motor alteration was not clinically evident, it
was detected by NCS (25 nerves: 57%). Both sensory and
motor alterations were signiﬁcantly more frequent in MB
over PB patients (χ2 = 7.25, P = 0.027).
No conduction was more commonly observed in the sen-
sory(17%)thanmotornerves(3%):19sural,followedbyﬁve
radial,threeulnar,andtwomedian,sensorynerves,andonly
in four motor nerves, namely the common peroneal nerve.
After excluding nonconducting nerves, prolonged latency
was the most frequent abnormality in both the sensory—
20.4% (30/147)—and motor—28.9% (37/128) nerves. Sen-
sory nerve action potential amplitude was reduced in 18.4%
(27/147)ofthenervesandcompoundmuscleactionpotential
amplitude, in 15.1% (58/384) of the stimulation sites. Veloc-
ity, the least-affected parameter among the sensory nerves
(4.1%[6/147]), was reduced in 21.8% (56/256) of the motor
nerve segments evaluated.
When inferring pathophysiological alteration by means of
NCS (after excluding nonconducting nerves), demyelinating
lesions (48%)—mainly among MB patients—predominated
as the nerve-conduction abnormality pattern (Table 3), fol-
lowedbytheoccurrenceofaxonallesionsin20(42%)nerves
(two PB and three MB). Mixed lesions, however, were ob-
served in only ﬁve (10%).
All patients were reevaluated one year after cessation of
MDT. As in the ﬁrst evaluation, NFI was frequently observed
(68% of the patients). However, while all the MB patients
had NFI, considerable improvement was observed in the PB
cases(Table1),leadingtoasigniﬁcantdifferencebetweenthe
two groups (χ2 = 12.320, P = 0.001), mainly regarding SNF
impairment. A total of four PB patients recovered full nerve
function. Even so, despite overall clinical improvement, the
frequency of nerve enlargement was stationary and 50% of
these patients recovered sensory improvement. Conversely,
thefrequencyofnerveenlargementincreasedamongtheMB
patients (10 patients) in conjunction with worsening in SNF
impairment.
Among the 12 (55%) patients with sensory impairment,
all had thermal and/or pain impairment in at least one im-
pairedsensorynerve;andfour(33%)alsohadtactileimpair-
ment in at least one of the affected nerves. Regarding motor
strength, impairments were detected in only three (14%)
patients (all MB). In addition, most patients recovered auto-
nomicfunction,asrepresentedbytheSVMR(n=4)andSSR
(n = 7).
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Table 3. Number of nerves (%) according to lesion patterns on nerve conduction study in leprosy groups.
Lesion patterns on NCS result
Group Axonal Demyelination Mixed No conduction Total altered
At diagnosis
PB 5 (50) 1 (10) 0 (0) 4 (40) 10 (100)
MB 15 (21) 22 (31) 5 (7) 29 (41) 71 (100)
∗P 0.314 0.003 0.203 0.006 <0.001
Follow-up
PB 1 (9) 6 (55) 0 (0) 4 (36) 11 (100)
MB 19 (40) 10 (21) 7 (14) 12 (25) 48 (100)
∗P 0.011 0.418 0.203 0.254 <0.001
NCS, nerve conduction study; PB, paucibacillary; MB, multibacillary.
∗P value of Mann–Whitney U test.
Fourpatients(threePB)(18%)hadanormalNCS.Among
the 18 patients (39% PB and 61% MB) with an abnormal
NCS, 17 (94%) had an abnormal sensory NCS (35% PB and
65% MB), and 17 (94%) had an abnormal motor NCS (41%
PB and 59% MB). Except for one MB patient, all patients
recovered from temporal dispersion.
Nerve conduction was recovered in most nerves, but par-
ticularlyintheradial,median,andcommonperonealnerves.
Yet, no conduction was obtained from 13 sural and three ul-
nar nerves. As to the number of affected nerves, a signiﬁcant
improvement (χ2 = 6.3, P = 0.012) was observed in MB pa-
tients while PB patients remained about the same (Table 3).
However,eventhoughtheaxonallesionsofmostPBpatients
(n = 3) improved, those of MB patients (n = 4) worsened.
Conversely, three PB patients had demyelination while eight
MB patients recovered from demyelination (P = 0.029).
Five MB patients (21%) developed type 2 reaction, four
haderythemanodosumleprosumduringMDT,andonehad
multiform erythema after release from treatment. Since the
patients had exclusively cutaneous lesions without clinical
signsorsymptomsofneuritis,theyweretreatedwiththalido-
mide for an average of 13 months (3–27 months). The one
patient with multiform erythema also received oral pred-
nisone for nine months. However, nerve function worsened
in two of these patients later diagnosed to be without clin-
ical symptoms. On admission, all but one patient enduring
leprosy reaction had an altered neurological examination.
Discussion
Leprosyneuropathyisaparticularlycomplexailmentinview
of the superposition of acute and chronic sensory, motor,
and/or autonomic events. It is important to recognize that,
in many leprosy patients, nerve damage may occur with or
without symptoms from the very beginning of infection. It
has been reported that NFI at diagnosis varies from 9.8%
in a cohort of 315 PB patients from Bangladesh (Richardus
et al. 1996) to 55% in Ethiopia (Van Brakel et al. 2005). In
the present sample, the use of additional clinical parameters
to evaluate NFI may have contributed to the higher rate of
NFIthanhasbeencustomarilyfound.Likewise,ahighpreva-
lence of abnormality in NCS parameters has been reported
by various authors at the moment of diagnosis, of up to 92%
in MB patients (Capadia et al. 2010) and even in clinically
unaffected nerves (McLeod et al. 1975).
In the present study, a different frequency of both clinical
and neurophysiological nerve function alteration was ob-
served between the PB and MB patients assessed. As seen by
other authors (Richardus et al. 1996), more MB than PB pa-
tients had NFI at leprosy diagnosis. Croft et al. (2000) found
that 21% of PB patients with NFI at diagnosis experienced
new NFI events during the second year of evaluation. In ad-
dition, other authors (Samant et al. 1999), regardless of the
detection of NFI at diagnosis, have reported a higher fre-
quency of nerve function worsening among PB (20%) over
MB (13%) patients at the end of MDT both clinically and/or
electrophysiologically. This difference could be due to the
earlier period of follow-up evaluation in the latter study. It
should also be taken in consideration that reaction may de-
velop after MDT (Nery et al. 2006) leading to NFI, and NCS
alterations may take a longer time than NFI to recover from
damage (Jardim et al. 2007).
A high prevalence of peripheral autonomic dysfunction,
ranging from 43% to 62%, has been observed in newly di-
agnosed leprosy patients (Abbot et al. 1996; Illarramendi et
al. 2005). In the present study, however, a lower prevalence
of autonomic dysfunction was seen. This difference may be
explained by the inclusion of SVMR and SSR evaluations of
the lower extremities in previous studies (Abbot et al. 1996;
Wilder-Smith and Wilder-Smith 1996). Again, in the present
study, SSR and SVMR were more efﬁcient than the clinical
examination at detecting small ﬁber neuropathy. In addi-
tion, both tests managed to detect almost all clinical SNF
dysfunctions.
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A clear recovery of autonomic function was observed dur-
ing follow-up, both clinically and in the SSR and SVMR
evaluations. Although both tests evaluate the sympathetic
function, the reﬂex pathways are different (Low et al. 1983;
Shahanietal.1984),whichmayberesponsibleforthehigher
improvement rate observed in SSR as compared to SVMR.
Moreover, SVMR impairment, while strongly associated to
leprosy reaction (Illarramendi et al. 2005), has been shown
to recover after steroid therapy (Wilder-Smith and Wilder-
Smith 1997).
Consistentwithpreviousﬁndings,SNFwasmorefrequent
than LNF impairment, conﬁrming that, in leprosy, small
and unmyelinated nerve ﬁber involvement is more extensive
thanLNFinvolvement(Dasturetal.1973).Furthermore,the
prevalence of sensory impairment was higher than the inci-
dence of motor dysfunction, also in conformity with other
studies(Solomonetal.1998;Jardimetal.2003).Thedissoci-
ation between SNF and LNF impairment is explained by the
factthat,inleprosy,thenervefasciclesareunevenlyimpaired.
Nerve ﬁber involvement is a complex phenomenon with the
simultaneous presence of segmental de- and remyelination
concomitant with Wallerian degeneration of preferentially
small myelinated ﬁbers (Gibbels et al. 1988).
In this study, demyelinating lesions were more frequently
observed in motor nerves, although previous studies (van
Brakel et al. 2008) have demonstrated that sensory nerves
are committed earlier. It can be justiﬁed by the fact that mo-
tor NCS was performed in proximal segments while sensory
NCS was only evaluated distally. In leprosy neuropathy, mo-
tor nerve conduction shows higher rates of abnormality in
entrapment segments such as ulnar nerve in elbow segment,
peroneal nerve in peroneal head segment. So, we observed
higher slowed velocity among motor than sensory nerves
since only the distal segment was evaluated in the latter.
In terms of NCS, and as reported by other authors, the
patients worsened overall; and abnormalities persisted, par-
ticularly in the lower limbs, despite clinical improvement
(Samant et al. 1999). A two- to threefold higher percent-
age of deterioration over improvement of sensory and mo-
tor nerve function was shown in 365 MB patients (Capadia
et al.2010).However,the majority(64%)hadalreadyshown
involvement of more than ﬁve nerves and a high prevalence
of reaction (39%) upon admission to the study. Nonetheless,
s o m er e c o v e r yc o u l db eo b s e r v e dw h e nn u m b e ro fn e r v e s
and type of lesion were considered. Regarding nonconduct-
ing nerves, improvement was also evident in both PB and
MB patients. Predominance of no conduction has been ob-
served in sensory nerves by other authors, with rates as high
as 45% in the sural nerves demonstrating improvement in
5% of these same nerves (Capadia et al. 2010) despite lep-
rosy reaction. The differences in deterioration and recovery
rates, however, may be attributed to the presence of reaction,
the timely administration of steroid treatment, the longer
duration of NFI, and/or type of leprosy evaluated in these
studies.
Again, in the present study, at leprosy diagnosis, there was
a higher incidence of demyelinating lesions. However, in-
dicative of axonal loss, low amplitudes have been found as
the most important early electrodiagnostic ﬁnding in lep-
rosy neuropathy (Singh et al. 1977; Thacker et al. 1996; Van
Brakel et al. 2005). These changes have been shown to be
mainly conﬁned to compound muscle action potential and
sensorynerveactionpotential,particularlyregardingtheten-
dernerves.Thisdifferencemaybeduetothefactthatthepa-
tientsinthepresentstudywerefreeofneuritisatdiagnosis,as
decreased velocity is produced by the inﬂammatory oedema
of the nerves during acute neuritis (Thacker et al. 1996).
The variable nerve patterns detected in the NCS lesions
in conjunction with the variations in the damage found
within the many nerves studied clearly highlight the above-
mentioned complex nature of nerve damage in leprosy, even
in such a small patient sample, suggesting that a thorough
nerve evaluation is essential to be able to delineate a more
realistic picture of the patient at hand. Thus, leprosy neu-
ropathy studies should, in principle, never be limited to only
one or even just a couple of particular nerves but expanded
t oi n c l u d ea l lt h ep e r i p h e r a ln e r v e s .
NCS allowed for the diagnosis of neuropathy better than
the clinical parameters. As expected, there was less NCS al-
teration in patients with normal tactile sensation than in
patients with SFN. While other authors have not found ad-
vantages in motor nerve conduction over voluntary muscle
testing (Samant et al. 1999), the former made it possible to
detect motor neuropathy in patients with normal voluntary
muscle testing. High NCS sensibility has been reported by
others as well (van Brakel et al. 2008; Khambati et al. 2009).
NCS is useful for detecting and evaluating the extension of
leprosy neuropathy (van Brakel et al. 2008).
Leprosy neuropathy remains a signiﬁcant medical chal-
lenge because it may develop during any of the phases of
the disease and its evolution depends on a number of factors
that are both difﬁcult to evaluate and, ultimately, control.
Full neurological evaluation of the peripheral nerves of each
patient is recommended at different stages in a focused ef-
fort to decipher the ongoing clinical and neurophysiological
patterns of neuropathy. In addition, recovery depends on a
numberofothervariablessuchaspointintimeofrecognition
and treatment of neuritis, number and extent of reactional
episodes, and the clinical form of the disease, all of which
should determine the need for additional surveillance.
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